Opendata, web and dolomites


Tailored cell-based therapies for frontotemporal dementia and related genetically defined CNS orphan indications

Total Cost €


EC-Contrib. €






 iProg project word cloud

Explore the words cloud of the iProg project. It provides you a very rough idea of what is the project "iProg" about.

implantable    clinical    biotherapeutics    biotechnology    company    restores    phasei    brd    exposure    repair    systemic    negligible    solutions    medicine    market    modifying    leverage    generation    first    efficacy    manner    gene    successful    populations    failing    candidates    therapeutic    suffer    diseases    pgrn    orphan    innovation    thereby    explore    cns    sme    vision    conduct    changers    overcome    treatment    driver    patients    ftd    safe    severe    disorders    right    iia    device    detect    transforming    signals    unmet    ing    instrument    therapies    frame    neurotrophic    sinfonia    mutations    lay    entirely    locally    drug    causative    reaching    indications    lower    lives    progranulin    situ    combat    safety    efficacious    biologics    standards    medical    ultimately    tech    desired    brain    framework    game    degeneration    therapy    levels    proprietary    patient    neurodegenerative    paving    iprog    genetically    disease    prepare    frontotemporal   

Project "iProg" data sheet

The following table provides information about the project.


Organization address
postcode: 141 57
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Project website
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-12-01   to  2019-05-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 


 Project objective

Sinfonia Biotherapeutics is a high-tech biotechnology company. Our vision is to become a main driver in technology innovation for CNS medicine, where we lay the frame-work for entirely novel therapeutic concepts and solutions that combat the unmet medical need of severe CNS conditions, ultimately transforming patient lives. We are developing targeted therapies for genetically defined CNS orphan indications that are built on a proprietary medical device – the Brain Repair Device - that overcome several of the existing challenges associated with the failing clinical development of drug candidates for neurodegenerative diseases today. The BRD is an implantable device that allows for the in situ production of our therapeutic biologics resulting in desired CNS exposure, while the systemic exposure of the therapeutic factor is negligible. We are developing a new generation of tailored biologics for genetically defined disease/patient populations that target the disease locally in the brain. With our therapies we are thus reaching the right patient, with the right treatment, in an efficacious and safe manner. Through the SME Instrument, we will focus on further developing iProg, a novel neurotrophic therapy that restores progranulin levels in the brain of patients that suffer from frontotemporal degeneration due to mutations in the PGRN gene (FTD/PGRN), which results in lower progranulin production and is disease-causative. We will use the SME Instrument funding (Phase 1&2) to prepare and conduct PhaseI/IIa studies to explore the safety and detect the first signals of efficacy of iProg. If successful, the project will set new standards on the biologics for neurodegenerative disease market, paving a way to growth and new potential partnerships for Sinfonia. Our disease-modifying therapies have the potential to leverage an important framework for therapeutic development in neurodegenerative disorders in general and thereby to become real game changers in CNS medicine.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IPROG" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IPROG" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More  

PAROST (2019)

Disruptive technology for the identification, quantification and prediction of the evolution of damages in civil engineering structures that increases safety while reducing maintenance costs.

Read More  

C-Air (2018)

An innovative, reliable, lifesaving industrial air purification system that contains, cleans, and purifies air contaminated by toxic gases.

Read More